The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2016 | Why the rapid development of new drugs poses new challenges
Kostas Stamatopoulos, MD, PhD from CERTH Institute of Applied Biosciences, Thessaloniki, Greece discusses the issues associated with the rapid development of new drugs in chronic lymphocytic leukemia (CLL). One key issue is affordability and access according to Dr Stamatopoulos. The other issue is linked to the high pace of development of novel drugs concerns adverse events or late events.
Recorded at the European Hematology Association (EHA) 2016 Annual Congress in Copenhagen, Denmark.
